 1. Male or female patients with one of the following: a loss of heterozygosity LOH at 3p14 andor 9p21 in the oral IEN of patients with a history of curatively treated oral cancer or b LOH at 3p14 andor 9p21 plus at one other chromosomal region in the IEN of patients with no oral cancer history. 